Sensex, Nifty Slip In Early Trade

Indian shares opened a tad lower on Monday as French elections pointed to a hung parliament and investors looked ahead to the release of the U.S. inflation print for June as well as Federal Reserve Chair Jerome Powell\'s testimony this week for additional clues on the Fed\'s rate trajectory. The benchmark S&P/BSE Sensex dropped 180...

Read More

Regeneron Pharma Expects Q4 Results To Include $24 Mln In Acquired In-process R&D Charge

Regeneron Pharmaceuticals, Inc. (REGN) said Monday it currently expects that its financial results for the second quarter 2024 will include an acquired in-process research and development charge of approximately $24 million on a pre-tax basis. This charge relates to up-front payments, as well as a premium on equity securities purchased, in connection with collaboration and...

Read More

KORE Group Appoints Bruce Gordon As EVP And COO

KORE Group Holdings, Inc. (KORE) announced Monday that Bruce Gordon has joined as Executive Vice President and Chief Operating Officer (COO), effective July 2, 2024. In his new roles, Gordon will focus on enhancing operational efficiencies, fostering innovation and driving sustainable growth. His leadership will help optimize KORE\'s internal processes, leverage human talent and maximize...

Read More

Outlook Therapeutics Says UK MHRA Grants Marketing Authorization For LYTENAVA To Treat Wet AMD

Biopharmaceutical company Outlook Therapeutics, Inc. (OTLK) announced Monday that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for LYTENAVA (bevacizumab gamma). LYTENAVA is the first and only authorized ophthalmic formulation of bevacizumab for use in treating wet AMD in the EU and UK. This approval comes after Outlook...

Read More